Dose escalation
DLTs
The DLT-evaluable population comprised 38 and 16 patients in the monotherapy and combination therapy escalation cohorts, respectively (Supplementary Figure 1). No DLTs occurred in either cohort. The oleclumab 40 mg/kg dose was the protocol-specified maximum administered dose and was used in the expansion phase based on evaluation of all available safety, PK, pharmacodynamic biomarker, and preliminary antitumor activity data in the dose-escalation phase, described below.